Article
Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues.
Nucleic acid therapeutics - 1 Oct 2017
Aartsma-Rus Annemieke, Straub Volker, Hemmings Robert, Haas Manuel, Schlosser-Weber Gabriele, Stoyanova-Beninska Violeta, Mercuri Eugenio, Muntoni Francesco, Sepodes Bruno, Vroom Elizabeth, Balabanov Pavel
Abstract excerpt
Duchenne muscular dystrophy (DMD) is a rare, severe, progressive muscle-wasting disease leading to disability and premature death. Patients lack the muscle membrane-stabilizing protein dystrophin. Antisense oligonucleotide (AON)-mediated exon skipping is a therapeutic approach that aims to induce production of partially functional dystrophins. Recently, an AON targeting exon 51 became the first of its class to be...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.